<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310243</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 23-14</org_study_id>
    <nct_id>NCT02310243</nct_id>
  </id_info>
  <brief_title>Study of Palbociclib in MLL-rearranged Acute Leukemias</brief_title>
  <official_title>Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationales Centrum für Tumorerkrankungen Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age ≥ 18 years, no upper age
      limit Study drug: Palbociclib Phase Ib/IIa, open-label

        -  Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days
           followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell
           lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and
           glioblastoma, this regimen will be chosen for the first dose to be evaluated in the
           phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib
           for the phase IIa is defined.

        -  Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib
           part of the study is administered once daily for 21 days followed by 7 days of rest.
           Based on the optimal two-stage design of Simon, 21 patients are treated in the first
           stage. If results are positive, 29 additional patients will be recruited into the second
           stage of the study. An efficacy of the investigational therapy will be rejected in the
           first stage of 21 treated patients if two or less patients achieve complete remission
           (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or
           anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during
           this first stage, the trial is intended to be continued in the second stage with a total
           sample size of 50 patients.

      Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient
      out): July 2018 The treatment duration of an individual patient is estimated to be 2-6
      months, but may be unlimited in patients with sustained response (&quot;case-by-case decision&quot;).

      Observation time per patient after entry into the study (incl. treatment) is at least 12
      months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of palbociclib</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of target (CDK6) inhibition by palbociclib</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.
phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>oral, once daily (125mg, 100mg or 75mg) for 21 days</description>
    <arm_group_label>Palbociclib</arm_group_label>
    <other_name>PD-0332991-00</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according
             to the 2008 WHO Classification

          -  Patients with MLL-rearranged leukemia who are refractory to standard induction therapy
             and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

          -  Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment
             and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)

          -  Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for
             intensive first-line therapy

          -  Genetic/histologic/immunohistologic assessment in one of the central laboratories

          -  Age ≥ 18 years, no upper age limit

          -  WHO performance status of ≤ 2

          -  No prior chemotherapy two weeks before study entry except hydroxyurea to control
             hyperleukocytosis

          -  Non-pregnant and non-nursing. Women of child-bearing potential must have a negative
             serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours
             prior to registration (WOCBP is defined as a sexually active mature woman who has not
             undergone a hysterectomy or who has had menses at any time in the preceding 24
             months).

          -  Female patients in the reproductive age and male patients must agree to avoid getting
             pregnant or to father a child while on therapy and for three months after the last
             dose of therapy.

          -  Women of child-bearing potential must either commit to continued abstinence from
             heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal
             ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of
             birth control.

          -  Men must agree not to father a child and must use a latex condom during any sexual
             contact with WOCBP while receiving therapy and for three months after therapy is
             stopped, even if they have undergone successful vasectomy.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Prior treatment with palbociclib

          -  Performance status &gt; 2 according to WHO criteria

          -  Organ insufficiency: creatinine &gt; 1.5 x upper normal serum level; bilirubin, AST, or
             AP &gt; 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled
             hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or
             restrictive ventilation disorder

          -  Uncontrolled infection

          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin
             cancer. Patients are not considered to have a &quot;currently active&quot; malignancy if they
             have completed therapy and are considered by their physician to be at less than 30%
             risk of relapse within one year.

          -  Severe neurologic or psychiatric disorder interfering with ability of giving informed
             consent

          -  Known or suspected active alcohol or drug abuse

          -  Known positivity for HIV, active HAV, HBV, or HCV infection

          -  Bleeding disorder unrelated to leukemia

          -  Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is
             allowed)

          -  QTc &gt; 470 msec (based on the mean value of triplicate ECGs), family or personal
             history of long or short QT syndrome, Brugada syndrome, or known history of QTc
             prolongation or Torsade de Pointes

          -  Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging
             drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)

          -  No consent for registration, storage, and processing of individual disease
             characteristics, information on the course of the disease, and information obtained
             from the family physician and/or other physicians involved in the treatment of the
             patient about study participation

          -  No consent for biobanking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schmid, MD</last_name>
      <email>christoph.schmid@klinikum-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Schöndube, MD</last_name>
      <email>daniel.schoendube@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Bladus, MD</last_name>
      <email>claudia.baldus@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, MD</last_name>
      <email>maike.dewit@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
      <email>joerg.westermann@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Tina Mayer, MD</last_name>
      <email>karin.mayer@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Krauter, MD</last_name>
      <email>krauter.juergen@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schroeder, MD</last_name>
      <email>thomas.schroeder@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Wattad, MD</last_name>
      <email>m.wattad@kliniken-essen-sued.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, MD</last_name>
      <email>nadezda.basara@malteser.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>791016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Wäsch, MD</last_name>
      <email>ralph.waesch@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Distelrath, MD</last_name>
      <email>distelrath@mvz-osthessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maisun Abu Samara, MD</last_name>
      <email>maisun.abu.samra@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Fiedler, MD</last_name>
      <email>fiedler@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heuser, MD</last_name>
      <email>heuser.michael@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alwin Krämer, MD</last_name>
      <email>Alwin.Kraemer@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, MD</last_name>
      <email>mark.ringhoffer@klinikum-karlsruhe.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-August Horst, MD</last_name>
      <email>h.horst@med2.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, MD</last_name>
      <email>stephankremers@onkologie-lebach.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uni-Klinikum der Otto-von-Guericke-Universität</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, MD</last_name>
      <email>denise.wolleschak@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kindler, MD</last_name>
      <email>thomas.kindler@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, MD</last_name>
      <email>frank.griesinger@pius-hospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Salih, MD</last_name>
      <email>Helmut.Salih@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Paschka, MD</last_name>
      <phone>0049-731-500</phone>
      <phone_ext>45521</phone_ext>
      <email>peter.paschka@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Peter Paschka</investigator_full_name>
    <investigator_title>PD. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>MLL-rearranged leukemia</keyword>
  <keyword>Palbociclib (PD-0332991-00)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

